Knoxville, TN – According to filings with the U.S. Securities and Exchange Commission, Provectus Biopharmaceuticals is raising $5,000,000.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Heather Raines played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Provectus Biopharmaceuticals
Provectus Biopharmaceuticals vision is to make our innovative medicines equitably accessible and financially affordable to patients and their families and caregivers around the world. Provectus is a clinical-stage biotechnology company developing immunotherapy medicines based on small molecules called halogenated xanthenes, the entire class of which is owned by our company. Provectus lead molecule is called rose bengal disodium. Based on different formulations and routes of administration, our clinical and non-clinical data indicate how Provectus drug platform may treat different indications across a diverse range of disease areas that include oncology, dermatology, hematology, virology, microbiology, and ophthalmology. Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers. Developing Safe, Affordable, and Accessible Immunotherapy Medicines that Maximize Curative Impact.

To learn more about Provectus Biopharmaceuticals, visit http://www.provectusbio.com/

Contact:
Heather Raines, Chief Financial Officer
866-594-5999

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved